Cathepsin L Helps to Defend Mice from Infection with Influenza A.
Identifieur interne : 000C02 ( PubMed/Curation ); précédent : 000C01; suivant : 000C03Cathepsin L Helps to Defend Mice from Infection with Influenza A.
Auteurs : Xiang Xu [États-Unis] ; John R. Greenland [États-Unis] ; Jeffrey E. Gotts [États-Unis] ; Michael A. Matthay [États-Unis] ; George H. Caughey [États-Unis]Source :
- PloS one [ 1932-6203 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Cathepsine L (pharmacologie), Femelle, Infections à Orthomyxoviridae (traitement médicamenteux), Lymphocytes T CD4+ (), Mâle, Pneumopathie infectieuse (traitement médicamenteux), Pneumopathie infectieuse (virologie), Poumon (virologie), Souris, Souris de lignée C57BL, Sous-type H1N1 du virus de la grippe A ().
- MESH :
- pharmacologie : Cathepsine L.
- traitement médicamenteux : Infections à Orthomyxoviridae, Pneumopathie infectieuse.
- virologie : Pneumopathie infectieuse, Poumon.
- Animaux, Femelle, Lymphocytes T CD4+, Mâle, Souris, Souris de lignée C57BL, Sous-type H1N1 du virus de la grippe A.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Cathepsin L.
- drug effects : CD4-Positive T-Lymphocytes, Influenza A Virus, H1N1 Subtype.
- drug therapy : Orthomyxoviridae Infections, Pneumonia.
- virology : Lung, Pneumonia.
- Animals, Female, Male, Mice, Mice, Inbred C57BL.
Abstract
Host-derived proteases can augment or help to clear infections. This dichotomy is exemplified by cathepsin L (CTSL), which helps Hendra virus and SARS coronavirus to invade cells, but is essential for survival in mice with mycoplasma pneumonia. The present study tested the hypothesis that CTSL protects mice from serious consequences of infection by the orthomyxovirus influenza A, which is thought to be activated by host-supplied proteases other than CTSL. Ctsl-/- mice infected with influenza A/Puerto Rico/8/34(H1N1) had larger lung viral loads and higher mortality than infected Ctsl+/+ mice. Lung inflammation in surviving infected mice peaked 14 days after initial infection, accompanied marked focal distal airway bronchiolization and epithelial metaplasia followed by desquamation and fibrotic interstitial remodeling, and persisted for at least 6 weeks. Most deaths occurred during the second week of infection in both groups of mice. In contrast to mycoplasma pneumonia, infiltrating cells were predominantly mononuclear rather than polymorphonuclear. The histopathology of lung inflammation and remodeling in survivors was similar in Ctsl-/- and Ctsl+/+ mice, although Ctsl+/+ mice cleared immunoreactive virus sooner. Furthermore, Ctsl-/- mice had profound deficits in CD4+ lymphocytes before and after infection and weaker production of pathogen-specific IgG. Thus, CTSL appears to support innate as well as adaptive responses, which confer a survival advantage on mice infected with the orthomyxovirus influenza A.
DOI: 10.1371/journal.pone.0164501
PubMed: 27716790
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C02
Links to Exploration step
pubmed:27716790Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cathepsin L Helps to Defend Mice from Infection with Influenza A.</title>
<author><name sortKey="Xu, Xiang" sort="Xu, Xiang" uniqKey="Xu X" first="Xiang" last="Xu">Xiang Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Greenland, John R" sort="Greenland, John R" uniqKey="Greenland J" first="John R" last="Greenland">John R. Greenland</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gotts, Jeffrey E" sort="Gotts, Jeffrey E" uniqKey="Gotts J" first="Jeffrey E" last="Gotts">Jeffrey E. Gotts</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Matthay, Michael A" sort="Matthay, Michael A" uniqKey="Matthay M" first="Michael A" last="Matthay">Michael A. Matthay</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Caughey, George H" sort="Caughey, George H" uniqKey="Caughey G" first="George H" last="Caughey">George H. Caughey</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27716790</idno>
<idno type="pmid">27716790</idno>
<idno type="doi">10.1371/journal.pone.0164501</idno>
<idno type="wicri:Area/PubMed/Corpus">000C02</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C02</idno>
<idno type="wicri:Area/PubMed/Curation">000C02</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cathepsin L Helps to Defend Mice from Infection with Influenza A.</title>
<author><name sortKey="Xu, Xiang" sort="Xu, Xiang" uniqKey="Xu X" first="Xiang" last="Xu">Xiang Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Greenland, John R" sort="Greenland, John R" uniqKey="Greenland J" first="John R" last="Greenland">John R. Greenland</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gotts, Jeffrey E" sort="Gotts, Jeffrey E" uniqKey="Gotts J" first="Jeffrey E" last="Gotts">Jeffrey E. Gotts</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Matthay, Michael A" sort="Matthay, Michael A" uniqKey="Matthay M" first="Michael A" last="Matthay">Michael A. Matthay</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Caughey, George H" sort="Caughey, George H" uniqKey="Caughey G" first="George H" last="Caughey">George H. Caughey</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of California at San Francisco, San Francisco, California</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>CD4-Positive T-Lymphocytes (drug effects)</term>
<term>Cathepsin L (pharmacology)</term>
<term>Female</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Lung (virology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Orthomyxoviridae Infections (drug therapy)</term>
<term>Pneumonia (drug therapy)</term>
<term>Pneumonia (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Cathepsine L (pharmacologie)</term>
<term>Femelle</term>
<term>Infections à Orthomyxoviridae (traitement médicamenteux)</term>
<term>Lymphocytes T CD4+ ()</term>
<term>Mâle</term>
<term>Pneumopathie infectieuse (traitement médicamenteux)</term>
<term>Pneumopathie infectieuse (virologie)</term>
<term>Poumon (virologie)</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Sous-type H1N1 du virus de la grippe A ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Cathepsin L</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term>
<term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Orthomyxoviridae Infections</term>
<term>Pneumonia</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Cathepsine L</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Pneumopathie infectieuse</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Pneumopathie infectieuse</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
<term>Pneumonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Lymphocytes T CD4+</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Host-derived proteases can augment or help to clear infections. This dichotomy is exemplified by cathepsin L (CTSL), which helps Hendra virus and SARS coronavirus to invade cells, but is essential for survival in mice with mycoplasma pneumonia. The present study tested the hypothesis that CTSL protects mice from serious consequences of infection by the orthomyxovirus influenza A, which is thought to be activated by host-supplied proteases other than CTSL. Ctsl-/- mice infected with influenza A/Puerto Rico/8/34(H1N1) had larger lung viral loads and higher mortality than infected Ctsl+/+ mice. Lung inflammation in surviving infected mice peaked 14 days after initial infection, accompanied marked focal distal airway bronchiolization and epithelial metaplasia followed by desquamation and fibrotic interstitial remodeling, and persisted for at least 6 weeks. Most deaths occurred during the second week of infection in both groups of mice. In contrast to mycoplasma pneumonia, infiltrating cells were predominantly mononuclear rather than polymorphonuclear. The histopathology of lung inflammation and remodeling in survivors was similar in Ctsl-/- and Ctsl+/+ mice, although Ctsl+/+ mice cleared immunoreactive virus sooner. Furthermore, Ctsl-/- mice had profound deficits in CD4+ lymphocytes before and after infection and weaker production of pathogen-specific IgG. Thus, CTSL appears to support innate as well as adaptive responses, which confer a survival advantage on mice infected with the orthomyxovirus influenza A.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27716790</PMID>
<DateCompleted><Year>2017</Year>
<Month>06</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>10</Issue>
<PubDate><Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Cathepsin L Helps to Defend Mice from Infection with Influenza A.</ArticleTitle>
<Pagination><MedlinePgn>e0164501</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0164501</ELocationID>
<Abstract><AbstractText>Host-derived proteases can augment or help to clear infections. This dichotomy is exemplified by cathepsin L (CTSL), which helps Hendra virus and SARS coronavirus to invade cells, but is essential for survival in mice with mycoplasma pneumonia. The present study tested the hypothesis that CTSL protects mice from serious consequences of infection by the orthomyxovirus influenza A, which is thought to be activated by host-supplied proteases other than CTSL. Ctsl-/- mice infected with influenza A/Puerto Rico/8/34(H1N1) had larger lung viral loads and higher mortality than infected Ctsl+/+ mice. Lung inflammation in surviving infected mice peaked 14 days after initial infection, accompanied marked focal distal airway bronchiolization and epithelial metaplasia followed by desquamation and fibrotic interstitial remodeling, and persisted for at least 6 weeks. Most deaths occurred during the second week of infection in both groups of mice. In contrast to mycoplasma pneumonia, infiltrating cells were predominantly mononuclear rather than polymorphonuclear. The histopathology of lung inflammation and remodeling in survivors was similar in Ctsl-/- and Ctsl+/+ mice, although Ctsl+/+ mice cleared immunoreactive virus sooner. Furthermore, Ctsl-/- mice had profound deficits in CD4+ lymphocytes before and after infection and weaker production of pathogen-specific IgG. Thus, CTSL appears to support innate as well as adaptive responses, which confer a survival advantage on mice infected with the orthomyxovirus influenza A.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Greenland</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Veterans Affairs Medical Center, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gotts</LastName>
<ForeName>Jeffrey E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Matthay</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Caughey</LastName>
<ForeName>George H</ForeName>
<Initials>GH</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Veterans Affairs Medical Center, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>IK2 CX001034</GrantID>
<Acronym>CX</Acronym>
<Agency>CSRD VA</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K12 HL119997</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 3.4.22.15</RegistryNumber>
<NameOfSubstance UI="D056668">Cathepsin L</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056668" MajorTopicYN="N">Cathepsin L</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>07</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>09</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27716790</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0164501</ArticleId>
<ArticleId IdType="pii">PONE-D-16-29305</ArticleId>
<ArticleId IdType="pmc">PMC5055332</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2011 Apr 11;208(4):643-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21402738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Jun 10;308(5728):1643-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15831716</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2011 Oct 28;147(3):525-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22036562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 May;88(10):5608-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24600012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Pathol. 2008;3:499-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18039138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 Jan 29;18(2):274-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22286307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2010 Sep;20(5):298-310</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20629046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Chem Biol. 2014 Dec;23:8-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25213682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2012 Jan;1824(1):68-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22024571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2010 Oct;120(10):3421-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20921628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2012;6(12):e1923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23236527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2500-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21868704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1999 May 25;258(1):1-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10329563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2001 Jun;15(8):1481-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11387264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2002 Jul 5;277(27):24609-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11986312</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2007 Apr 17;115(15):2065-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17404153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Mar 5;303(5663):1529-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14976261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cell Biol. 2015 Jul-Sep;94(7-9):375-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26095298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 May;88(9):4744-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24522916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biophys Biomol Struct. 1999;28:181-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10410800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2005 Oct;207:229-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16181340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2016 Apr 1;310(7):L689-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26747784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1998 Apr 17;280(5362):450-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9545226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Oct;79(20):12714-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16188974</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2013 Sep;49(3):437-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23600672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2016 Mar 09;7:93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27014272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2015 Jan 29;517(7536):621-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25533958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2013;9(12):e1003774</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24348248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2011 Mar 15;411(2):216-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21236461</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000C02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:27716790 |texte= Cathepsin L Helps to Defend Mice from Infection with Influenza A. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27716790" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |